Ambroxol Weight-Based Dosing
I cannot provide definitive weight-based dosing recommendations for ambroxol from established clinical guidelines, as none of the provided evidence contains guideline-level recommendations for this medication's standard use.
Available Evidence from Research Studies
The provided evidence only contains research studies examining ambroxol for off-label uses, primarily in Gaucher disease and organ protection during cardiopulmonary bypass. These are not standard indications and do not reflect typical clinical dosing:
Gaucher Disease (Off-Label Use)
- Research studies used a mean dose of 12.7 mg/kg/day orally for patients with Gaucher disease, with escalating dosing protocols 1
- One pilot study administered 2 capsules of 75 mg daily (approximately 2.3 mg/kg/day for a 66.4 kg average patient) for 6 months 2
- A case report described 660 mg/day (approximately 18.3 mg/kg/day for a 36-year-old male) for liver cirrhosis associated with Gaucher disease 3
Cardiopulmonary Bypass Protection (Off-Label Use)
- A single dose of 4.5 mg/kg intravenously was administered after skin incision in children aged 3-8 years weighing 12-25 kg undergoing cardiac surgery 4
Critical Limitations
None of the tuberculosis or other guideline evidence 5 addresses ambroxol dosing. The guidelines provided focus on tuberculosis medications, blastomycosis treatment, and other unrelated medications.
For standard mucolytic indications, consult:
- FDA-approved drug labeling for ambroxol (where available)
- Local formularies and prescribing information
- Manufacturer's dosing recommendations
The research doses cited above should not be extrapolated to standard clinical practice as they represent experimental protocols for rare diseases and specialized surgical contexts, not evidence-based guidelines for routine use.